Maintenance Tx With Guselkumab for UC Meets All Endpoints

The monoclonal antibody in development as maintenance therapy for people with moderately to severely active ulcerative colitis was more effective than placebo.

Related Keywords

Chicago ,Illinois ,United States ,Massachusetts ,Boston ,Washington ,David Rubin ,Guselkumab Tremfya ,Ashwin Ananthakrishnan ,Janssen Johnson ,Drug Administration ,Colitis Center At Massachusetts ,Digestive Disease Week ,Medscape Medical ,Inflammatory Bowel Disease Questionnaire ,Colitis Center ,Massachusetts General Hospital ,